Pakjoo M, Ahmadi S, Zahedi M, Jaafari N, Khademi R, Amini A
Cell Commun Signal. 2024; 22(1):105.
PMID: 38331801
PMC: 10851565.
DOI: 10.1186/s12964-023-01433-5.
Xie Z, Meng J, Kong W, Wu Z, Lan F, Narengaowa
Aging Cell. 2022; 21(3):e13565.
PMID: 35181976
PMC: 8920437.
DOI: 10.1111/acel.13565.
Hardianti B, Umeyama L, Li F, Yokoyama S, Hayakawa Y
Mol Med Rep. 2020; 22(6):5385-5391.
PMID: 33173971
PMC: 7647032.
DOI: 10.3892/mmr.2020.11615.
Li D, Yang W, Ren J, Ru Y, Zhang K, Fu S
J Virol. 2019; 93(23).
PMID: 31534043
PMC: 6854495.
DOI: 10.1128/JVI.01438-19.
Mothersill C, Rusin A, Seymour C
Cancers (Basel). 2019; 11(9).
PMID: 31450803
PMC: 6770832.
DOI: 10.3390/cancers11091236.
CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death.
Chung A, Leisner T, Dardis G, Bivins M, Keller A, Parise L
Cancer Cell Int. 2019; 19:26.
PMID: 30740034
PMC: 6360800.
DOI: 10.1186/s12935-019-0740-2.
TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.
Yang J, LeBlanc F, Dighe S, Hamele C, Olson T, Feith D
Blood. 2018; 131(25):2803-2815.
PMID: 29699990
PMC: 6014359.
DOI: 10.1182/blood-2017-09-808816.
Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays.
Perera S, Wang B, Damian A, Dyer W, Zhou L, Conceicao V
Microarrays (Basel). 2016; 5(2).
PMID: 27600080
PMC: 5003490.
DOI: 10.3390/microarrays5020014.
Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms.
Bumdelger B, Kokubo H, Kamata R, Fujii M, Yoshimura K, Aoki H
PLoS One. 2016; 11(1):e0147088.
PMID: 26783750
PMC: 4718675.
DOI: 10.1371/journal.pone.0147088.
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
Duru A, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B
PLoS One. 2015; 10(9):e0138248.
PMID: 26378933
PMC: 4574561.
DOI: 10.1371/journal.pone.0138248.
The Critical Role of Proteolytic Relay through Cathepsins B and E in the Phenotypic Change of Microglia/Macrophage.
Ni J, Wu Z, Peterts C, Yamamoto K, Qing H, Nakanishi H
J Neurosci. 2015; 35(36):12488-501.
PMID: 26354916
PMC: 6605404.
DOI: 10.1523/JNEUROSCI.1599-15.2015.
Surviving apoptosis: life-death signaling in single cells.
Flusberg D, Sorger P
Trends Cell Biol. 2015; 25(8):446-58.
PMID: 25920803
PMC: 4570028.
DOI: 10.1016/j.tcb.2015.03.003.
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed M, Alharbi S
Exp Biol Med (Maywood). 2015; 240(6):760-73.
PMID: 25854879
PMC: 4935211.
DOI: 10.1177/1535370215579167.
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.
Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M
Cell Death Dis. 2014; 5:e1444.
PMID: 25299769
PMC: 4649511.
DOI: 10.1038/cddis.2014.404.
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Neumann S, Hasenauer J, Pollak N, Scheurich P
J Biol Chem. 2014; 289(23):16576-87.
PMID: 24764293
PMC: 4047423.
DOI: 10.1074/jbc.M114.559468.
Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker.
Krieg A, Mersch S, Wolf N, Stoecklein N, Verde P, am Esch 2nd J
BMC Cancer. 2013; 13:384.
PMID: 23937794
PMC: 3751299.
DOI: 10.1186/1471-2407-13-384.
Membrane trafficking of death receptors: implications on signalling.
Schneider-Brachert W, Heigl U, Ehrenschwender M
Int J Mol Sci. 2013; 14(7):14475-503.
PMID: 23852022
PMC: 3742255.
DOI: 10.3390/ijms140714475.
The African Fusarium/maize disease.
Dutton M
Mycotoxin Res. 2013; 25(1):29-39.
PMID: 23604934
DOI: 10.1007/s12550-008-0005-8.
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.
Azijli K, Weyhenmeyer B, Peters G, de Jong S, Kruyt F
Cell Death Differ. 2013; 20(7):858-68.
PMID: 23579241
PMC: 3679459.
DOI: 10.1038/cdd.2013.28.
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim J, Jin D, Lee W, Hur D, Wu T, Kim D
Pharmacol Res. 2013; 71:23-33.
PMID: 23428347
PMC: 3817614.
DOI: 10.1016/j.phrs.2013.02.001.